Avalo Therapeutics, Inc.

DB:C6K0 Stock Report

Market Cap: €38.4m

Avalo Therapeutics Management

Management criteria checks 2/4

Avalo Therapeutics' CEO is Garry Neil, appointed in Feb 2022, has a tenure of 3.25 years. total yearly compensation is $7.21M, comprised of 7.4% salary and 92.6% bonuses, including company stock and options. directly owns 0.44% of the company’s shares, worth €169.60K. The average tenure of the management team and the board of directors is 3.3 years and 2 years respectively.

Key information

Garry Neil

Chief executive officer

US$7.2m

Total compensation

CEO salary percentage7.38%
CEO tenure3.3yrs
CEO ownership0.4%
Management average tenure3.3yrs
Board average tenure2yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Garry Neil's remuneration changed compared to Avalo Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2025n/an/a

US$73m

Dec 31 2024US$7mUS$533k

-US$35m

Sep 30 2024n/an/a

-US$102m

Jun 30 2024n/an/a

-US$113m

Mar 31 2024n/an/a

-US$143m

Dec 31 2023US$1mUS$475k

-US$32m

Sep 30 2023n/an/a

-US$33m

Jun 30 2023n/an/a

-US$25m

Mar 31 2023n/an/a

-US$30m

Dec 31 2022US$1mUS$469k

-US$42m

Sep 30 2022n/an/a

-US$51m

Jun 30 2022n/an/a

-US$72m

Mar 31 2022n/an/a

-US$76m

Dec 31 2021US$1mUS$423k

-US$84m

Sep 30 2021n/an/a

-US$81m

Jun 30 2021n/an/a

-US$77m

Mar 31 2021n/an/a

-US$73m

Dec 31 2020US$3mUS$373k

-US$64m

Compensation vs Market: Garry's total compensation ($USD7.21M) is above average for companies of similar size in the German market ($USD493.58K).

Compensation vs Earnings: Garry's compensation has been consistent with company performance over the past year.

CEO

Garry Neil (70 yo)

3.3yrs
Tenure
US$7,212,749
Compensation

Dr. Garry A. Neil, M.D., serves as the Member of Scientific Advisory Board of Rapafusyn Research And Development, Inc. Dr. Garry serves as Independent Director of Celldex Therapeutics, Inc. since June 16,...

Leadership Team

NamePositionTenureCompensationOwnership
Garry Neil
President3.3yrsUS$7.21m0.44%
€ 169.6k
Christopher Sullivan
CFO & Head of Investor relations3.3yrsUS$2.93m0.16%
€ 60.9k
Mittie Doyle
Chief Medical Officerless than a yearUS$3.26mno data
Solomon Snyder
Founder and Chairman of Scientific Advisory Boardno datano datano data
Barbara Slusher
Founder and Member of Scientific Advisory Boardno datano datano data
Paul Varki
Chief Legal Officerless than a yearno datano data
Lisa Hegg
Senior Vice President of Program Management3.3yrsno datano data
Colleen Matkowski
Senior Vice President of Global Regulatory Affairs & Quality Assurance3.3yrsno datano data
Dino Miano
Senior Vice President of CMC & Technical Operations3.3yrsno datano data
Jennifer Riley
Chief Strategy Officerless than a yearno datano data
3.3yrs
Average Tenure
59yo
Average Age

Experienced Management: C6K0's management team is considered experienced (3.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Garry Neil
President2.9yrsUS$7.21m0.44%
€ 169.6k
Solomon Snyder
Founder and Chairman of Scientific Advisory Boardno datano datano data
Barbara Slusher
Founder and Member of Scientific Advisory Boardno datano datano data
Sol Barer
Special Advisor & Strategic Advisory Board3.9yrsUS$133.94kno data
Michael Heffernan
Independent Chairman of the Boardless than a yearno datano data
Ronald Borchardt
Member of Scientific Advisory Boardno datano datano data
Robert Lenox
Member of Scientific Advisory Boardno datano datano data
Anne Young
Member of Scientific Advisory Boardno datano datano data
Dennis Liotta
Member of Scientific Advisory Boardno datano datano data
Aaron Kantoff
Independent Director1.2yrsno data0.030%
€ 11.4k
Samantha Truex
Independent Director1.2yrsUS$339.74k0.030%
€ 11.4k
Mitchell Chan
Independent Director3.4yrsUS$362.48k0.030%
€ 11.4k
2.0yrs
Average Tenure
60yo
Average Age

Experienced Board: C6K0's board of directors are not considered experienced ( 2 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/20 07:12
End of Day Share Price 2025/05/20 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Avalo Therapeutics, Inc. is covered by 12 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Julian HarrisonBTIG
Raghuram SelvarajuH.C. Wainwright & Co.
Edward WhiteH.C. Wainwright & Co.